Chemotherapy of leishmaniasis: Recent advances in the treatment of visceral disease

Current Opinion in Infectious Diseases

Volumn 11, Issue 6, 1998, Pages 707-710

  Berman, Jonathan ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; PAROMOMYCIN;

HUMAN; REVIEW; VISCERAL LEISHMANIASIS;

EID: 0032406948     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199812000-00009     Document Type: Review

References (13)

1. Desjeux P. Leishmaniasis: public health aspects and control. Clin Dertmatol 1996; 14:417-423.
2. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298-319. This is a comprehensive review of visceral leishmaniasis in the HIV-infected population; and includes a thorough discussion of incidence, immunological defects, clinical presentation and treatment.
3. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24:684-703. A comprehensive review of clinical leishmaniasis: visceral, cuteneous, and mucosal, which includes the latest information on clinical presentation, diagnostic techniques and drugs.
4. Davidson RN, DiMartino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Quart J Med 1994; 87:75-81.
5. Davidson RN, DiMartino L, Gradoni L, et al. Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22:938-943.
6. Thakur CP, Pandey AK, Sinha GP, et al. Comparison of three treatment regimens of liopsomal amphotericin B (AmBisom) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90:319-322.
7. Berman JD, Badaro R, Thaku CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull WHO 1998; 76:25-32. A summary of dose-ranging studies of AmBisome for non-European visceral leishmaniasis. Data supporting present recommendations for African, Indian and South American disease are provided.
8. Dietze R, Milan EP, Berman JD, et al. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993; 17:981-986.
9. Dietze R, Fagundes SMS, Brito EF, et al. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995; 89:309-311.
10. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Int Med 1997; 127:133-137. A dose-ranging study of Abelcet for visceral leishmaniasis in India is described.
11. Jha TK, Olliaro P, Thakur CPN, et al. Randomized controlled trial of aminosidine (paromomycin) vs sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998; 316:1200-1205. A dose-ranging study of aminosidine for visceral leishmaniasis in India is described.
12. Walsh TJ, Yaldanci V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neurtopenic patients. Antimicrob Agents Chemother 1998; 42:2391-2398. A full description of the clinical side effects of AmBisome is presented.
13. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84:221-225.